Pharmafile Logo
Pharmafocus logo
Advanced Search

ASCO

Showing 15 posts of 55 posts found.

national-cancer-institute-kmvohcb-w5g-unsplash_1

AstraZeneca shares oncology data at ASCO 2023

May 25, 2023
Medical Communications ASCO, AstraZeneca, Cancer, Oncology, oncology

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting on …

News
astrazeneca_sign_sky

AZ and MSD impress at ASCO with Lynparza combo data in prostate cancer

June 5, 2018
Research and Development ASCO, AstraZeneca, Cancer, MSD< pharma, Merck, lynparza, prostate cancer

In another major ASCO reveal, AstraZeneca and partner MSD lifted the curtain at the event on new data for its …

News
nektar-therapeutics

“Underwhelming” drug data devastates Nektar, shares fall by 42%

June 5, 2018
Manufacturing and Production, Research and Development ASCO, BMS, Bristol-Myers Squibb, Cancer, Nektar, bristol myers-squibb, pharma

Nektar Therapeutics has seen its share price devastated after revealing disappointing trial data for its candidate NKTR-214 in combination with …

News
janssen_latest_logo_on_sign_closer

Janssen debuts promising new cancer data at ASCO

June 4, 2018
Research and Development, Sales and Marketing ASCO, Cancer, J&J, JJ, Jassen, erdafitinib, imbruvica, pharma

Janssen took the opportunity at the American Society of Clinical Oncology (ASCO) annual event to present promising new Phase 2 …

News
roche

Roche’s breast, lung cancer offerings fail to impress at ASCO

June 4, 2018
Research and Development, Sales and Marketing ASCO, Cancer, Roche, breast cancer, lung cancer, pharma, taselisib, tecentriq

Roche made an underwhelming impact at the American Society of Clinical Oncology (ASCO) annual event in Chicago, after revealing data …

News

Unprecedented CAR-T data shows 100% response rate

June 7, 2017
Research and Development ASCO, CAR T, CAR-T

Researchers celebrated a world-first at the American Society of Clinical Oncology conference, revealing data which showed that, in a study …

News
shutterstock_187433765

New targeted therapy promises strong response rate across 17 cancer types

June 5, 2017
Research and Development, Sales and Marketing ASCO, Cancer, Loxo Oncology, oncology

Loxo Oncology’s lead therapy larotrectinib made a big impact at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, …

News
msd

MSD says Phase III trials for Keytruda to treat advanced melanoma shows better survival

June 8, 2016
Research and Development ASCO, MSD, Merck & Co, PD-L1, advanced melanoma, drug trial, immuno-oncology, keytruda

Merck & Co (NYSE: MRK) said late-stage trials for its immunotherapy Keytruda (pembrolizumab) to treat advanced melanoma showed over half …

News
ascologo

Drug Pricing: Cancer drugs cost the most in US, but most unaffordable in India, China – Study

June 7, 2016
Medical Communications, Research and Development, Sales and Marketing ASCO, Drug pricing, oncology, social

Cancer drugs are less affordable in low-income countries, despite the lower retail prices, according to a study released at the …

Feature
clinical_trial_4

The Pharmafocus ASCO round-up

June 7, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASCO, Pharmafocus

As the curtain falls on another annual ASCO (American Society of Clinical Oncology) congress, catch up on all the biggest …

Feature
astrazeneca_plaque

AstraZeneca says latest study data for Lynparza suggest improvement in overall survival in ovarian cancer

June 7, 2016
Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AstraZeneca, NHS, lynparza, ovarian cancer, regulation

UK drugmaker AstraZeneca (LSE: AZN) said mid-stage trials for Lynparza (olaparib) maintenance therapy suggest an improvement in overall survival (OS) …

News
amgen_flag

Amgen showcases positive Phase III multiple myeloma drug at ASCO

June 7, 2016
Manufacturing and Production, Research and Development ASCO, Amgen, Kyprolis, dexamethasone, lenalidomide, multiple myeloma

Amgen (NASDAQ: AMGN) has presented data showing a statistically significant increase in progression-free survival and overall response rate in multiple …

News
novartis_outside_1

Novartis says Phase II data for rare lung cancer showed overall response rate of 63%

June 7, 2016
Manufacturing and Production, Research and Development, Sales and Marketing ASCO, Novartis, Tafinlar, drug trial, lung cancer, mekinist

Swiss drugmaker Novartis (VTX: NOVN) said combination mid-stage trials for the drug to treat a rare and aggressive form of …

News
test_results

Pivotal avelumab data in Merkel cell carcinoma presented at ASCO

June 6, 2016
Manufacturing and Production, Research and Development ASCO, Merck, Pfizer, avelumab, merkel cell carcinoma

New data presented at the American Society of Clinical Oncology’s annual general meeting has shown that avelumab, an investigational anti-PD-L1 …

News
abbvie_0

AbbVie says Stemcentrx’ lung cancer drug shows some benefits in early trials

June 6, 2016
Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AbbVie, Stemcentrx, drug trial, lung cancer, rova-t

US drug firm AbbVie (NYSE: ABBV) said its early-stage trials for its drug to treat an aggressive form of lung …

News
News alerts and subscriptions

Latest content

FDA approves first oral antiviral to treat adult patients with COVID-19

May 26, 2023

Scientists use AI to find new antibiotic to fight superbug

May 26, 2023

ZOLL remedē System receives FDA approval for sleep apnoea treatment

May 25, 2023
volodymyr-hryshchenko-m1hq4ibp9rc-unsplash

BioInvent and Transgene announce positive phase 1a solid tumour trial data

May 25, 2023

ElevateBio announced $401m in Series D financing for cell and gene therapies

May 25, 2023